Introduction
The extracellular signal-regulated kinase (ERK)-signaling pathway plays a crucial role in various cellular responses including cell proliferation, growth, differentiation and survival by relaying extracellular signals from ligand-bound cell surface tyrosine kinase receptors to gene transcription in nucleus via a cascade of specific phosphorylation events (1) . Aberrant activation of this pathway due to increased exposure to growth factors, overexpression or mutation of receptor tyrosine kinases, Ras and Raf, has been implicated in many aspects of tumorigenesis including proliferation, differentiation, invasion, angiogenesis and apoptosis (2, 3) . Recent studies have identified several negative regulators such as mitogen-activated protein kinase phosphatases (MKPs), Spred and Sef that can modulate duration, magnitude and subcellular compartmentalization of ERK1/2 activity, suggesting that these inhibitor proteins also play important roles in tumorigenesis (4) (5) (6) . In ovarian cancer, constitutive activation of ERK activity has been associated with high tumorigenicity and chemoresistance (7, 8) . Therefore, the ERK pathway is a crucial target for therapeutic intervention in ovarian cancer.
MKP3 is a member of the subfamily of protein tyrosine phosphatases known as dual-specificity phosphatases (MKPs) (9, 10) . Biochemical and structural studies have shown that MKP3 is capable of dephosphorylating ERK1/2 by protein-protein interactions via mitogenactivated protein kinase interaction motif within the N-terminal ERK1/ 2-binding domain (11) . Moreover, MKP3 negatively modulates ERK1/2 but not p38 and c-jun N-terminal kinase activities (12, 13) . Recent studies have shown that MKP3 is underexpressed in pancreatic cancer due to promoter hypermethylation and frequent loss of heterozygosity (14, 15) . Overexpression of MKP3 has shown to have apparent tumorsuppressive effects through reduction of phosphorylated ERK1/2 in a dose-dependent manner in pancreatic cancer cells (16, 17) . However, there is lack of similar reports in other human cancers so far.
In the present study, we analyzed the expression levels of MKP3 ovarian cancer samples and cell lines. We provide here the mechanistic correlation between oxidative stress and ubiquitination/proteosome degradation of MKP3 protein in ovarian cancer cells. Functional analyses employing MKP3 knockdown and ectopically overexpression revealed the role of MKP3 in negatively regulating ERK1/2 activity and inhibiting tumorigenicity and chemoresistance in vitro and in vivo.
Materials and methods

Clinical samples and cell lines
Seventy-seven tissue samples of surgically resected primary ovarian cancer and 41 normal ovary samples from women who had surgery for benign diseases such as uterine fibroids were randomly selected for this study. All the clinical specimens used in the present study were approved by the local institutional ethics committee (UW 05-143 T/806). Six immortalized human ovarian surface epithelial (HOSE) cells, HOSE 6-3, HOSE 10-2, HOSE 11-12, HOSE 17-1, HOSE 20-3 and HOSE 21-3, and ovarian cancer cell lines, OV2008, C13 Ã , A2780s, A2780cp, DOV13-5, OVCAR3, SKOV3, OV420, OV429 and OV433 (American Type Culture Collection, Rockville, MD), were used in this study.
Plasmids and RNA interference
The MKP3-expressing construct, pcDNA3.1/V5-His-DUSP6/MKP3, and the HA-tagged ubiquitin-expressing construct, pcDNA-HA(Ub) 8 , have been used previously (16, 18) . The MKP3 mutant-expressing construct, pcDNA3.1/V5-His-DUSP6/mut-MKP3, was generated by creating point mutations at serines 159 and 197. The short hairpin RNA interference targeting MKP3 (target sequence: TACACGAGCCGTCTAGATTGG) was ligated into pcDNA TM 6.2-GW/EMGFP-miR plasmid (Invitrogen Life Technology, Carlsbad, CA). Three synthetic small interfering RNAs specific for human MKP3 were provided and synthesized by Ambion (Ambion K.K., Tokyo, Japan).
Quantitative and semiquantitative reverse transcription-polymerase chain reaction Total RNA from each cell line was prepared by TRIzol reagent (Invitrogen Life Technology). First-strand complementary DNA was synthesized by random hexamers and Taqman reverse transcription reagent kit (Applied Biosystems, Foster city, CA). For real-time quantitative reverse transcription-polymerase chain reaction, the amount of MKP3 messenger RNA (mRNA) was quantified by TaqMan Gene Expression Assays and in an ABI 7700 system (Applied Biosystems). The MKP3 primers and probe were obtained from Applied Biosystems (Assay ID: Hs00169257_m1). Each sample was performed in triplicate and normalized with human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Assay ID: Hs99999905_m1; Applied Biosystem). For semiquantitative reverse transcription-polymerase chain reaction, the MKP3 mRNA level was evaluated by a pair of primers-MKP3-sense 5#-CTACCTG-GAAGGTGGCTTCA-3# and MKP3-antisense 5#-GTTGGACAGCGGAC-TACCAT-3#-with the following conditions for 30 cycles: denaturation at Abbreviations: ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H 2 O 2 , hydrogen peroxide; HOSE, human ovarian surface epithelial; MKP, mitogen-activated protein kinase phosphatase; mRNA, messenger RNA; NAC, N-acetyl-L-cysteine; ROS, reactive oxygen species. 94°C for 20 s, annealing at 54°C for 20 s and extension at 72°C for 20 s. The relative amount of MKP3 was normalized using GAPDH mRNA with the following primers: GAPDH-sense-5#-ACGCATTTGGTCGTATTGGG-3# and GAPDH-antisense-5#-TGATTTTGGAGGGATCTCGC-3# and amplification at 25 cycles: denaturation at 94°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 1 min.
Western blot analysis
Harvested cells were lysed by Cell Lysis Buffer (Cell Signaling Technology, Beverly, MA) supplemented with Protease Inhibitor Cocktail (Sigma Chemical Co., St Louis, MO). For western blot analyses, samples containing equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotted onto Immobilon-P Transfer Membrane (Millipore Corporation, Bedford, MA). Blots were blocked with 5% skim milk, followed by incubation with antibodies specific for anti-phospho p44/42 ERK1/2 (Thr202/Tyr204, Cell Signaling Technology), anti-ERK1/2 (Chemicon International, Temecula, CA), anti-MKP3 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA), anti-b-actin (AC-74, Sigma Chemical Co), anti-HA (12CA5, Roche Diagnostics Corp, Indianapolis, IN) and anti-V5 (Invitrogen), respectively. Blots were then incubated with goat anti-rabbit or anti-mouse secondary antibody conjugated to horseradish peroxidase (Amersham Pharmacia, Cleveland, OH) accordingly.
In vivo ubiquitination assay
This assay was done as described by Chan et al. (18) . Briefly, A2780cp cells were seeded onto 100 mm culture plates. The plasmids, pcDNA3.1/V5-His-DUSP6/MKP3 and pcDNA-HA(Ub) 8 , were cotransfected into A2780cp cells, respectively, using FuGENE TM 6 transfection kit (Roche Diagnostics Corp). Cells were then harvested in NET lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl and 5 mM ethylenediaminetetraacetic acid) with 1% NP40, pH 8.0, 0.1 mM phenylmethylsulfonyl fluoride and 1 mM Complete TM protease inhibitor cocktail (Roche). One milligram of cell lysate was incubated with 1 lg of mouse anti-IgG and anti-V5 antibodies at 4°C. After incubation, 40 ll of Protein A/G Plus-Agarose beads (Santa Cruz Biotechnology) was added to each sample and the mixture was rotated overnight at 4°C. After centrifugation, the beads were washed four times with NET lysis buffer, followed by addition of 30 ll of 2Â sample buffer containing b-mercaptoethanol and boiled for 10 min prior to electrophoresis. The proteasome inhibitor, MG132, was obtained from Calbiochem (La Jolla, CA).
Determination of cellular hydrogen peroxide
To evaluate the production of cellular hydrogen peroxide (H 2 O 2 ), cells were seeded in 96-well plates and cultured in serum-free medium for 2 days. Intracellular generation of H 2 O 2 from these cells was detected by using fluorogenic substrate 2#,7#-dichlorodihydrofluorescein (DCF) diacetate (H2DCFDA, Calbiochem) and measured by a Tecan optical-fluorescence Plate Reader (485-530 nm, Tecan Group Ltd, Männedorf, Switzerland) (19) . The readings were normalized by cell numbers detected by Cell Proliferation Kit II (XTT) (Roche Diagnostics, Mannheim, Germany). This assay was performed in at least three independent experiments. The antioxidant, N-acetyl-L-cysteine (NAC), was used for the removal of intracellular reactive oxygen species (ROS) (Calbiochem).
Cell viability analysis
Cell viability was measured by Cell Proliferation Kit II (XTT) according to the manufacturer's instructions (Roche). The experiment was performed in triplicate for each time point. Cisplatin (CDDP) and mitogen-activated protein kinase/ ERK kinase 1/2 (MEK1/2) inhibitor PD98059 were obtained from Calbiochem.
Anchorage-independent growth assay in soft agar A total of 5 Â 10 3 cells were trypsinized and suspended in 2 ml of full medium plus 0.3% agar (Sigma). The agar-cell mixture was plated on top of a bottom 
In vivo tumorigenicity assay
This assay was done as described by Chan et al. (20) . To investigate the cisplatin resistance of MKP3 stably transfected A2780cp cells in vivo, 5 mg/ body wt (kg)/day of cisplatin (CDDP) (EBEWE Pharma Unterach, Austria) was administered intraperitoneally once for every 6 days with total of three injections into five nude mice when the size of every tumor became $3 mm in diameter. As a control group, physiological saline alone was used. All the animal experiments were approved by the University of Hong Kong Committee on the Use of Live Animals in Teaching and Research (CULATR No.1391-06).
Statistical analysis
Student's t-test (for parametric data) and the Mann-Whitney test (for nonparametric data) were used. A P-value was considered significant when ,0.05.
Results
MKP3 is underexpressed in ovarian cancer
Real-time quantitative reverse transcription-polymerase chain reaction analysis showed that SKOV3, OVCA429, OVCA433 and A2780cp expressed relatively lower levels of MKP3 mRNA ($2-to 10-fold reductions) as compared with HOSE cell lines ( Figure 1A ). But western blot analysis revealed that more ovarian cancer cell lines (OVCAR3, SKOV3, OVCA420, OVCA429, OVCA433, A2780cp and DOV13-5) expressed undetectable or lower MKP3 protein level ( Figure 1B) . Intriguingly, four cell lines (OVCAR3, OVCA420, OVCA433 and DOV13-5) expressed much lower MKP3 protein levels than their corresponding MKP3 mRNA expression levels ( Figure 1A and B). This scenario was much obvious in human ovarian cancer samples. No significant difference was observed in the amount of MKP3 mRNA between normal ovarian and cancer samples ( Figure 1C ). However, 40% of ovarian cancer samples showed downregulation of MKP3 protein expression levels when compared with normal ovarian samples (selected samples showed on Figure 1D ). These findings suggest that the loss of MKP3 protein predominates in ovarian cancer and the discrepancy between mRNA and protein expression levels of MKP3 may be due to a posttranscriptional regulation on MKP3 in ovarian cancer cells.
Loss of MKP3 is associated with ubiquitination/proteosome degradation To confirm the involvement of proteolysis in degrading MKP3 in ovarian cancer cells, we tested various pharmacological inhibitors of the cellular proteolytic system on two cell models A2780s and OV2008 (cisplatin-sensitive ovarian cancer cells) and A2780cp and C13
Ã (cisplatin-resistant variants). Both A2780cp and C13 Ã cell lines had relatively low expression protein levels of MKP3, but only A2780cp cells showed lower MKP3 mRNA (Figure 2A ). Upon treatment with MG132 at different doses (0, 5 and 10 lM) for 24 h, MKP3 expression was significantly restored in C13
Ã and A2780cp cells in a dose-dependent manner ( Figure 2B ), suggesting MKP3 protein may be degraded by ubiquitination/proteosome pathway. Figure 2C ). On the contrary, the degradation of MKP3 in both A2780cp and C13 Ã ovarian cancer cells was significantly inhibited by an antioxidant, NAC, in a dose-dependent manner and was further enhanced when cotreatment with MG132 (10 lM) ( Figure 2D ). However, unchanged levels of MKP3 mRNA were observed (data not shown). The restoration of MKP3 by treatment of NAC was further confirmed by in vivo ubiquitination assay using A2780cp cell model (supplementary Figure S1 is available at Carcinogenesis Online).
To further ascertain the role of H 2 O 2 in promoting MKP3 proteosome-mediated proteolysis, we performed the in vivo ubiquitination assay in HEK293T and A2780cp cells. Western blot analysis showed that the levels of ubiquitinated MKP3 were increased when treated with MG132 ( Figure 2E ). Such ubiquitinated MKP3 protein levels were further enhanced when treated by H 2 O 2 (1 mM) and/or MG132 ( Figure 2E ). However, high concentration of H 2 O 2 (10 mM) could not degrade MKP3 via ubiquitination/proteosome pathway but lead to extensive degradation via oxidative breakage on MKP3 protein (23) ( Figure 2E ). To test whether phosphorylation of MKP3 is the possible mechanism leading to proteasomal degradation of MKP3, the mut-MKP3-expressing plasmid (point mutations at serines 159 and 197 MKP3 phosphorylation sites) was transfected into HEK293T cells and treated with H 2 O 2 . Western blot analysis showed that both MKP3 and mut-MKP3 proteins were still degraded by H 2 O 2 treatment. However, the reduced level of mut-MKP3 was much less as compared with MKP3 (supplementary Figure S2 is available at Carcinogenesis Online). In vivo ubiquitination assay also revealed that the level of ubiquitinated mut-MKP3 was obviously reduced compared with ubiquitinated MKP3 under treatment of H 2 O 2 and/or MG132 (supplementary Figure S3 is available at Carcinogenesis Online). This indicates that the phosphorylation of MKP3 is associated with proteasomal degradation of MKP3. Taken together, these findings suggest that the loss of MKP3 is due to ROS-mediated degradation via the proteasome/ ubiquitination pathway in ovarian cancer cells and phosphorylation of MKP3 is the possible mechanism leads to ubiquitination/degradation.
MKP3 is a negative regulator to ERK1/2 in ovarian cancer cells
Previous studies have demonstrated that MKP3 acts as a negative regulator on ERK1/2-signaling pathway in pancreatic cancer Loss of MKP3 in ovarian cancer cells (16, 17) . In this study, our ovarian cancer cell lines and samples expressed low MKP3 but high phospho-ERK1/2 expression levels ( Figure 1B and D) . This similar scenario was observed in cisplatinsensitive ovarian cancer cells (A2780s and OV2008) and vice versa for their cisplatin-resistant variants (A2780cp and C13 Ã ) ( Figure 3A ). To investigate the regulatory mechanism of MKP3 on ERK1/2 activity, we employed vector-based RNAi (shMKP3) and was successfully depleted .70% endogenous MKP3 in A2780s cells (shMKP3 C4 and shMKP3 C6) ( Figure 3B ). We also used short interfering RNA (siMKP3#1 and siMKP3#3) to knock down .55 and .62% endogenous MKP3 in A2780s cells and OVCA433 cells, respectively ( Figure 3C ). As expected, the depletion of MKP3 was associated with the increased phospho-ERK1/2 levels in A2780s cells ( Figure 3B and C) . Conversely, ectopic expression of V5-tagged MKP3 (V5/MKP3) in A2780cp (C7, C13 and C19) and SKOV3 cells remarkably reduced the expression levels of phospho-ERK1/2 ( Figure 3D ). These data suggest that MKP3 negatively regulates ERK1/2 activity in ovarian cancer cells.
MKP3 inhibits tumorigenicity of ovarian cancer cells
Constitutive activation of ERK1/2 pathway has been shown to be associated with tumorigenicity in many cancers (24) . To determine the involvement of MKP3 in suppressing the tumorigenicity of ovarian cancer, we assessed both cell proliferation rate and anchorageindependent growth ability of MKP3-deficient ovarian cancer cell lines, C13
Ã and A2780cp. With XTT assay, both cisplatin-resistant cell lines, C13
Ã and A2780cp, showed higher cell proliferation rate ( Figure 4A ). Besides, A2780cp cells showed higher anchorageindependent growth ability by soft agar assay ( Figure 4B ).
On the other hand, depletion of MKP3 significantly increased cell proliferation rate and anchorage-independent growth ability in A2780s cells (shMKP3 C4 and shMKP3 C6) ( Figure 5A ). On the contrary, enforced MKP3 expression in A2780cp cells (C13 and C19) showed significant inhibition of cell proliferation and anchorageindependent growth ability ( Figure 5B ).
To further examine whether MKP3 could suppress in vivo tumorigenic activity of ovarian cancer cells, two MKP3 transfectants (C13 and C19) and the vector control of A2780cp cells were inoculated into nude mice. The tumor growth rates for both MKP3 transfectants (C13 and C19) were $2-fold slower compared with the vector control ( Figure 5C ). This could be confirmed by their tumor sizes on day 26 that the tumor size of vector control was 2111 ± 296 mm 3 , whereas C13 and C19 were 538 ± 79 mm 3 and 836 ± 93 mm 3 , respectively (P , 0.005 for C13 and P , 0.05 for C19) ( Figure 5C ). These data highlight the inhibitory functions of MKP3 on tumorigenicity in vitro and in vivo.
MKP3 reduces cisplatin resistance of ovarian cancer cells
It has been demonstrated that high ERK1/2 activity contributes to cisplatin resistance of ovarian cancer cells (25) . Two pairs of cell models including cisplatin-sensitive ovarian cancer cell lines (A2780s and OV2008) and their cisplatin-resistant counterparts (A2780cp and C13 Ã ) were examined (26) . Upon treatment with cisplatin (0, 5 and 10 lM) for 24 h, both cisplatin-sensitive cell lines, A2780s and OV2008, showed .2-fold reduction of cell viability when compared with their cisplatin-resistant counterparts ( Figure 6A ). Previous studies have demonstrated that pretreatment of cisplatinresistant ovarian cancer cells with MEK1/2 inhibitor, PD98059, may sensitize cells to cisplatin-induced apoptosis (8) . Consistent with this finding, we found that treatment of PD98059 (20 lM) could moderately sensitize both cisplatin-resistant cell lines, A2780cp and C13 Ã , to cisplatin-induced apoptosis by 0.4-to 1-fold ( Figure 6B ). On the contrary, under the same condition of cisplatin treatment, knockdown of MKP3 in A2780s cells (shMKP3 C4 and shMKP3 C6) significantly enhanced cisplatin resistance ( Figure 6C ), whereas enforced expression of MKP3 in A2780cp (C13 and C19) showed significant reduction of cisplatin resistance by 1-to 2.5-fold when compared with their vector controls ( Figure 6D ).
Next, we examined whether the above functions of MKP3 were associated with in vivo tumor growth in nude mice. We found that there were no differences in relative tumor sizes among any of the cisplatin treated or saline treated for the vector control groups ( Figure 6E ). However, for mice injected with MKP3 stably transfected A2780cp cells (C19), the relative tumor growth rate for cisplatin-treated group was significantly lower than that of saline-treated group ( Figure 6E) .
Discussion
In the present study, we have shown that the loss of MKP3 protein predominated in ovarian cancer and was inversely correlated with the ERK1/2 activity. Loss of MKP3 and high ERK1/2 activity was found to be associated with high intracellular H 2 O 2 accumulation, whereas mild treatment of ovarian cancer cells by H 2 O 2 resulted in MKP3 degradation through proteasome/ubiquitination pathway. We have investigated the molecular mechanism by which intracellular H 2 O 2 regulates MKP3 in ovarian cancer cells. Moreover, the decrease or increase of phospho-ERK1/2 levels due to ectopic overexpression of MKP3-or RNAi-mediated MKP3 knockdown indicates that ERK1/2 Ã ) with high phospho-ERK1/2 had faster cell proliferation rate compared with cisplatin-sensitive (A2780s and OV2008) ovarian cancer cells.
Ã P 5 0.025 and ÃÃ P 5 0.005. (B) The soft agar assay showed that A2780s and A2780cp had anchorage-independent growth ability. The A2780cp had higher anchorage-independent growth ability as compared with A2780s cells.
Ã P , 0.001.
activity is regulated by MKP3 in ovarian cancer cells. Interestingly, the reduction of ERK1/2 activity by restoration of MKP3 sensitized MKP3-deficient ovarian cancer cells to cisplatin-induced apoptosis and inhibited tumorigenicity of ovarian cancer cells in vitro and in vivo, suggesting that MKP3 possesses tumor-suppressive functions in ovarian cancer. To the best of our knowledge, this is the first study reporting such a regulatory mechanism between ROS and MKP3 expression in human cancers. Underexpression of MKP3 gene has been reported in pancreatic cancer due to promoter hypermethylation and allelic loss (15) . Our study also confirmed that MKP3 gene was underexpressed in some ovarian cancer cell lines. However, as we did not extensively investigate the mechanisms on silencing MKP3 genetically or epigenetically, we do not rule out that there may be other mechanisms causing silencing of expression of MKP3 in ovarian cancer. But the high discrepancy between the MKP3 protein and mRNA levels in ovarian cancer cell lines and cancer tissues indicates that the loss of MKP3 protein relatively predominates and may involve posttranscriptional modifications for MKP3 protein in ovarian cancer cells.
Increased ROS stress is common in cancer cells, which is attributed to the active metabolism from the effect of oncogenic signaling and/or mitochondrial malfunction during development and progression (27) (28) (29) . Previous studies have shown that the activity of MKP3 is inactivated by low concentration H 2 O 2 in cells (30, 31) . It is of interest to know whether the frequent loss of MKP3 is due to ROS-mediated degradation in ovarian cancer cells. Our data presented here clearly Ã P , 0.001. Right, the soft agar assay showed that knockdown of MKP3 in A2780s cells (shMKP3 C4 and shMKP3 C6) had higher anchorage-independent growth ability as compared with vector control.
Ã P , 0.01. (B) Left, XTT cell proliferation assay showed overexpression of MKP3 in A2780cp cells (C13 and C19) had reduction in cell proliferation rate as compared with vector control.
Ã P , 0.01. Right, the soft agar assay showed both MKP3 transfectants (C13 and C19) showed reduction of anchorage-independent growth ability as compared with vector control.
Ã P , 0.001. (C) Tumor formation assay in nude mice. Two MKP3 transfectants (C13 and C19) and vector control cells were inoculated subcutaneously into nude mice. Tumor formation in each nude mouse was monitored every 2 days for 26 days. The tumor size was calculated and depicted as mean tumor volume ± SE of five mice for each group. Both MKP3 transfectants (C13 and C19) had significant tumor growth rate ( Ã P , 0.05 and ÃÃ P , 0.005, respectively) as compared with vector control group.
Loss of MKP3 in ovarian cancer cells
demonstrated that the intracellular H 2 O 2 content was higher in MKP3-deficient ovarian cancer cells, A2780cp and C13 Ã , and this finding is consistent with other studies (32) . As expected, treatment of these cells by an antioxidant, NAC, could restore MKP3. Conversely, treatment of H 2 O 2 on MKP3-sufficient ovarian cancer cells, A2780s and OV2008, could degrade MKP3. As H 2 O 2 is capable of inducing protein ubiquitination/degradation (22, 33) , we have thus proved the degradation of MKP3 by low concentration of H 2 O 2 was mediated by the ubiquitin-proteasome system using proteasome inhibitor, MG132, and in vivo ubiquitination assay. Although we did not clarify the precise mechanism on MKP3 degradation via ubiquitination/ degradation pathways, increasing evidences have demonstrated that phosphorylation of MKP3 is the possible mechanism leading to proteasomal degradation of MKP3 (34, 35) . Indeed, numerous studies have shown that ROS is able to regulate the phosphorylation and ubiquitination of proteins such as Bcl-2 family proteins (36), p21 Waf1/Cip1 (37) and Arg tyrosine kinase (22) . We therefore examined whether the phosphorylation of MKP3 is associated with proteasomal degradation by generating point mutations at serines 159 and 197 of MKP3 according to recent reports (34, 35) . The loss-of-function mutation on these two phosphorylation sites of MKP3 could reduce the level of proteasomal degradation. However, certain level of proteasomal degradation on this mut-MKP3 was still observed, suggesting that there are other phosphorylation sites of MKP3 or interacting partners responsible for MKP3 proteasomal degradation. Recent studies have reported that casein kinase 2-alpha could interact and phosphorylate MKP3 (34, 38) . Protein casein kinase 2 is a ubiquitous Ser/Thr kinase and plays as anchoring elements and/or as a docking platform for proteins involved in ubiquitination such as the E2 ubiquitin-conjugating enzyme UBC3B (39, 40) . Therefore, further investigations are needed to investigate the relationship between casein kinase 2-alpha and the phosphorylation and degradation of MKP3. However, the present findings have clearly demonstrated that the frequent loss of MKP3 protein particularly in cisplatin-resistant and highly tumorigenic ovarian cancer cells is due to the accumulation of ROS during the development and progression of ovarian cancer. It is well known that constitutive activation of ERK-signaling pathway is crucially involved in the development of many cancers, including ovarian cancer. The overexpression of growth factor tyrosine kinase receptors or mutations in the Ras and BRAF gene families has been linked to aberrant activation of ERK pathway (2, 41) . This has attracted the exploration of anticancer agents targeting these receptors and kinases such as the Raf kinase inhibitor, BAY 43-9006, for the past decade (2) . However, there is still a lack of studies on the antitumorigenic functions of the negative regulators of ERK-signaling pathway. Recent studies have identified that MKPs negatively regulate the mitogen-activated protein kinase kinases by dephosphorylation and inactivation of the mitogen-activated protein kinase (9, 10) . MKP3, one of the MKPs members, was found to specifically bind to and inactivate ERK1/2 in mammalian cells (11) (12) (13) 42) . This means that MKP3 plays an important role in modulating the duration, magnitude and subcellular compartmentalization of ERK1/2 activity through a negative feedback mechanism (43) . Therefore, low MKP3 expression may compromise its ability to control ERK1/2 function activated by upstream factors such as tyrosine kinase receptors, mutated Ras or BRAF. Indeed, the loss of MKP3 has been found in pancreatic cancer (14) (15) (16) (17) . Consistent with these findings, we found that MKP3 was downregulated in ovarian cancer and this led to high levels of ERK1/2 activity. In fact, we have proved in this study that knockdown of endogenous MKP3 increased ERK1/2 activity which in turn enhanced cell proliferation and anchorage-independent growth ability of A2780s ovarian cancer cell line. On the contrary, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells inhibited their cell proliferation rate, anchorage-independent growth ability and tumor growth in nude mice.
Cisplatin is one of the most potent antitumor agents commonly used in ovarian cancer (44) . However, the major limitation of using this drug is the acquisition of resistance to initially responsive tumors (45) . Many studies have documented that constitutive activation of ERK1/2 is involved in cisplatin resistance in ovarian cancer, whereas inhibition of ERK1/2 activity by PD98059 can increase sensitivity to cisplatin-induced apoptosis (8, 46) . Similar to these findings, we demonstrated that inhibition of ERK1/2 activity by MKP3 could increase sensitivity of cisplatin-resistant ovarian cancer cells to cisplatininduced apoptosis and could inhibit tumor growth in nude mice. Interestingly, the enhanced sensitivity by MKP3 overexpression was much more obvious than PD98059 treatment. This suggests that constitutive expression of MKP3 in MKP3 transfectants has a stronger influence on the suppression of ERK1/2 activity and cisplatin resistance.
In conclusion, our results suggest that the loss of MKP3 is a crucial factor in the aberrant activation of ERK1/2 in ovarian cancer. Importantly, our findings indicate the accumulation of intracellular ROS may induce ubiquitination/degradation of MKP3 during the development and progression of ovarian cancer. The understanding of this molecular mechanism may assist the development of new therapeutic interventions for this disease.
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